image: Impacts of idiopathic hypersomnia; “n” is the number of people with idiopathic hypersomnia (PwIH) in the sample referring to each impact. Each PwIH could be included in more than one sub-domain for each impact domain.
Credit: Bermingham et al., 2025, PLOS One, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
Idiopathic hypersomnia is a rare disease of excessive sleepiness, with patients revealing they never feel rested or awake no matter how much sleep they get, in analysis of online posts
Article URL: http://plos.io/3KIF6W5
Article title: The experience and impact of living with idiopathic hypersomnia: A qualitative study of patient perspectives shared in online media
Author countries: U.S., Germany, Canada
Funding: This study was funded by Takeda Pharmaceuticals USA.
Journal
PLOS One
Article Title
The experience and impact of living with idiopathic hypersomnia: A qualitative study of patient perspectives shared in online media
Article Publication Date
22-Oct-2025
COI Statement
SLB is an employee of Takeda Pharmaceuticals USA., and stockholder of Takeda Pharmaceuticals Company, Ltd. AS and EB are employees of Gemic. DTP has served as a consultant and/or advisory board member for Aditum Bio, LLC, Alkermes, Centessa, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, and Teva Pharmaceuticals (Australia). This does not alter our adherence to PLOS ONE policies on sharing data and materials.